The U.S. Food and Drug Administration has approved a three-drug regimen to treat complicated urinary tract infections and complicated intra-abdominal infections, both of which can be especially problematic for people living with HIV.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Will potential study participants choose a vaccine trial over getting access to PrEP?
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.
Racism and Homophobia in Health Care Settings May Reduce PrEP Uptake for Young Black Gay and Bisexual Men, Study Finds
Racial segregation and medical mistrust in Milwaukee may keep pre-exposure prophylaxis out of their hands.
"The biggest barrier to care for transgender people is a lack of knowledgeable providers," said lead author Joshua D. Safer, M.D., with Mount Sinai Medical System.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
Could home-based self-swabs and mobile technology be helpful tools in the future of HIV prevention?
"We're very much putting the patient in the driver's seat," said Heather Alt, deputy director of nursing with Whitman-Walker. "If folks didn't feel ready, we would not push them to start."